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Abstract
Purpose: to investigate the factors affecting survival and toxicity in patients treated with stereotactic radiosurgery
(SRS), with special attention to volumes of brain receiving a specific dose (V10 - V16 Gy) as predictors for brain
radionecrosis.
Patients and Methods: Two hundred six consecutive patients with 310 cerebral metastases less than 3.5 cm were
treated with SRS as primary treatment and followed prospectively at University of Rome La Sapienza Sant’Andrea
Hospital. Overall survival, brain control, and local control were estimated using the Kaplan-Meier method calculated from
the time of SRS. Univariate and multivariate analysis using a Cox proportional hazards regression model were performed
to determine the predictive value of prognostic factors for treatment outcome and SRS-related complications.
Results: Median overall survival and brain control were 14.1 months and 10 months, respectively. The 1-year and
2-year survival rates were 58% and 24%, and respective brain control were 43% and 22%. Sixteen patients recurred
locally after SRS, with 1-year and 2-year local control rates of 92% and 84%, respectively. On multivariate analysis,
stable extracranial disease and KPS >70 were associated with the most significant survival benefit. Neurological
complications were recorded in 27 (13%) patients. Severe neurological complications (RTOG Grade 3 and 4)
occurred in 5.8% of patients. Brain radionecrosis occurred in 24% of treated lesions, being symptomatic in 10% and
asymptomatic in 14%. On multivariate analysis, V10 through V16 Gy were independent risk factors for radionecrosis,
with V10 Gy and V12 Gy being the most predictive (p = 0.0001). For V10 Gy >12.6 cm
3 and V12 Gy >10.9 cm
3 the
risk of radionecrosis was 47%.
Conclusions: SRS alone represents a feasible option as initial treatment for patients with brain metastases,
however a significant subset of patients may develop neurological complications. Lesions with V12 Gy >8.5 cm
3
carries a risk of radionecrosis >10% and should be considered for hypofractionated stereotactic radiotherapy
especially when located in/near eloquent areas.
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Introduction
Stereotactic radiosurgery (SRS) has become an increas-
ingly treatment option in the initial management of
patients with brain metastases. Its efficacy when used
alone or in combination with whole brain radiation-
therapy (WBRT) has been demonstrated in several
randomized trials and multi-institutional studies [1-8].
SRS plus WBRT is associated with better local tumor
control and functional autonomy for patients with brain
metastases when compared to WBRT alone, and with
significant longer survival in patients with a single
metastasis [3]. Recently, two large randomized studies
have shown similar survival benefits and functional
independence between patients with 1-3 brain metas-
tases treated with SRS alone and SRS plus WBRT [7,8].
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roughly equivalent to that reported after surgical resec-
tion [9]. Although surgery is usually indicated in
patients with lesions causing significant mass effect and
for large lesions > 3 cm in locations amenable to resec-
tion, in current clinical practice SRS is frequently
employed as less invasive and more cost-effective treat-
ment option than resection.
A variable rate of neurological complications of 2-14%
has been reported after SRS [7,8,10-17]; however, a
higher rate has been shown in some studies [1,18-20]
suggesting that patients may have side-effects after SRS
more often than reported. The most common complica-
tion of SRS is represented by the development of brain
radionecrosis that may occur in up to 50% of treated
lesions [21-26]. Factors related to the development of
radionecrosis after SRS include dose, treated volume,
and volume of the brain receiving a specific dose
[22,23,25-28]
In the present study we have reviewed our experience
with SRS in patients with brain metastases treated with
SRS alone as primary treatment. Related factors asso-
ciated with the clinical outcome and the development of
treatment-induced complications have been evaluated.
Patients and Methods
Between September 2006 and January 2010, 206 conse-
cutive patients aged 18 years or older with 1-3 cerebral
metastases less than 3.5 cm on contrast-enhanced mag-
netic resonance imaging (MRI), and derived from an
histologically confirmed systemic cancer, were treated
with SRS as primary treatment and followed prospec-
tively at University of Rome La Sapienza Sant’Andrea
Hospital. Patients who had received previous surgical
resection or WBRT, or receiving adjuvant WBRT fol-
lowing SRS were excluded from the study.
All metastatic tumors were treated with LINAC-based
SRS. The BrainLAB frameless stereotactic system, in
conjunction with the BrainScan treatment planning sys-
tem (Version 5.31) has been used for stereotactic treat-
ment. The target volume was identified on the basis of
the fused CT and magnetic resonance image (MRI)
scans. Radiosurgical dose was 20 Gy for metastases with
av o l u m e≤ 4.3 cm
3 (corresponding to a sphere of 2 cm
in diameter), 18 Gy for metastases with a volume of 4.3-
14.1 cm
3, and 15-16 Gy for metastases with a volume >
14.1 cm
3 or located in the brainstem. The gross tumor
volume (GTV) was delineated as a contrast-enhancing
tumor demonstrated on MRI scans. The planning target
volume (PTV) was generated by the geometric expan-
sion of GTV plus 1-2 mm. Doses were prescribed to the
80-90% isodose line normalized to the maximum dose.
Treatment volumes were achieved with 6-10 noncopla-
nar dynamic arcs by using a 6-MV LINAC. All patients
underwent a second CT (verification CT) scan before
the start of treatment in the CT-room and immediately
transferred to the treatment room in a wheel chair.
Planning and verification CT scans were fused employ-
ing a fusion algorithm included in the BrainLab plan-
ning system. The new coordinates of the isocenter were
recorded and the isocenter shift between verification
and planning CT calculated as previously reported [29].
This whole procedure takes less than 10 minutes. The
mask was refitted or the treatment replanned if the iso-
center shift was > 1.0 mm. Patients with multiple metas-
tases were treated in 2 or 3 following days in outpatient
clinic.
Patients were examined clinically one month after
radiosurgical treatment and then every 2 months. MRI
was made every 2 months in the first year after the
treatment, and then every 3 months or as appropriate
according to the neurological conditions. The size of
treated lesions was measured in three dimensions. Com-
plete and partial responses were defined as total radio-
graphic disappearance of lesion or decrease in tumor
volume > 50%. Local progression was defined as radio-
graphic increase in the size of metastatic lesion. For all
patients who died, the cause of death (intracranial ver-
sus extracranial progression) was determined by clinical/
neurological evaluation and brain/systemic radiologic
studies. Patients were considered to have died as result
of a neurological death if they had evidence of progres-
sive intracranial disease consisting of expanding intra-
cranial masses, CNS hemorrhage, progressive neurologic
symptoms, meningeal carcinomatosis, or hydrocephalus
resulting in herniation.
At each visit, neurological status and the severity of
complications were rated according to RTOG CNS toxi-
city criteria. Severe complications were considered to
have an RTOG Grade ≥ 3). Adverse neurological events
were considered consequence of SRS treatment if they
were associated or not to radiological abnormalities sug-
gestive of brain radionecrosis in absence of progressive
disease. Radionecrosis was assessed subjectively using
anatomic and dynamic susceptibility-weighted contrast-
enhanced (DSC) perfusion MRI. The following criteria
have been considered as suggestive of radionecrosis: 1)
increased T1 contrast enhancement located in the irra-
diated area with central hypointensity and increased per-
ipheral edema; 2) substantial regression or stability (for
at least 4 months) of enhancing areas on serial follow-
up MRI scans without additional treatment; 3) a clear
absence of perfusion (black hole), in the absence of any
nodular highly vascularized area within the contrast-
enhanced lesion at perfusion MRI. Enhancing lesion
that progressively increased in size on serial MR imaging
during a minimum follow-up period of 4 months was
scored as recurrent metastatic tumor. All diagnoses
Minniti et al. Radiation Oncology 2011, 6:48
http://www.ro-journal.com/content/6/1/48
Page 2 of 9were confirmed retrospectively by the same experienced
neuroradiological team (AB, AR, GT). Radionecrosis was
recorded as clinically symptomatic when associated with
neurological deterioration, whereas was recorded as
asymptomatic in patients who remained neurologically
stable.
MRI protocol
All MRI scans were obtained with a 1.5-T MRI scanner
(Siemens Sonata, Siemens Medical Systems, Erlangen,
Germany). After a localizing sagittal T1-weighted image,
non-enhanced axial T1-weighted spin echo (TR/TE,
600/12 ms) and axial T2-weighted (TR/TE 3,680/85)
images were obtained. Post-contrast axial and sagittal
(multiplanar reconstruction) T1-weighted imaging was
performed after the acquisition of the DSC MRI data.
DSC MRI scans were acquired using a T2-weighted
(TR/TE/flip angle:1.490/40/90°) EPI sequence. A
dynamic image series of 50 measurements performed on
14 axial sections with slice thickness 5 mm and inter-
slice gap 1.5 mm resulted in a total scan time of 1.20
min, with a field of view of 230-230 mm, matrix 128-
128 and an image acquisition matrix of 128 × 128, sig-
nal bandwidth 1502. A dose 0.1 mmol/kg bolus injection
of gadolinium contrast (Magnevist; Shering Diagnostics,
Berlin, Germany) delivered at the rate of 5 ml/s was
used. The post-processing of the DSC MRI data were
performed on a Leonardo VD10B Syngo OEM installa-
tion (Siemens AG).
Data analysis
Overall survival, brain control, and local control (control
of irradiated lesions) were estimated using the Kaplan-
Meier method calculated from the time of SRS. For uni-
variate analysis, the log-rank test was used for categori-
cal variables, and the Cox proportional hazards model
was used for continuous variables. The following factors
for outcome were tested: age (<65 vs ≥65 years), pre-
treatment KPS score (≤70 vs >70), number of brain
metastases (1 vs > 1), recursive partitioning analysis
(RPA) class (I vs II vs III), histology (lung vs breast vs
melanoma vs others), and extracranial disease (stable vs
active). Radionecrosis changes were assessed per tumor
a n de v e n t - f r e es u r v i v a lt i m eu s i n gt h eK a p l a n - M e i e r
method. Univariate analysis was performed to identify
risk factors for the presence of radionecrosis by using
the following patient and tumor determinants: sex, age,
histology, KPS score, tumor volume, SRS dose, volume
receiving a specific dose of 10,12,14,16 and 18 Gy (V10
Gy-V18 Gy), site of tumor, conformality index [30], and
homogeneity index. Prognostic factors for treatment
outcome and SRS-related complications found signifi-
cant (P < 0.05) were included in a multivariate outcome
with analysis performed using a Cox proportional
hazards regression model. In order to compare the own
results with previously published risk prediction models,
we have analyzed the correlation between V10 and V12
Gy and the increased risk of brain necrosis. Volumes
were divided in intervals determined by quantiles and
the risk of necrosis calculated in each interval. A prob-
ability value < 0.05 was considered statistically
significant.
Results
Patients and tumor characteristics
Two hundred six patients (109 males and 97 females)
with 310 metastases who underwent SRS between Sep-
tember 2006 and January 2010 and who met the pre-
viously described inclusion criteria were analyzed.
Tumor characteristics are listed in Table 1. One hun-
dred twenty-six patients (61%) were treated for 1 metas-
tasis, 56 (27%) for 2 metastases, and 24 patients (12%)
for 3 metastases. The median age at the time of SRS
was 62 years (range 26-81). The most common
Table 1 Summary of tumor characteristics and treatment
parameters
Parameter No(%)
number of patients 206
median age 62
sex (F/M) 99/107
no of lesions per patient
1 lesion 126 (61%)
2 lesions 56 (27%)
3 lesions 24 (12%)
histology
lung 106 (51%)
breast 38 (18%)
melanoma 34 (17%)
others 28 (14%)
tumor location
frontal 68 (22%)
parietal 78 (25%)
temporal 62 (20%)
cerebellar 43 (14%)
occipital 45 (15%)
brainstem 14 (4%)
radiosurgical dose (Gy)
20 118 (38%)
18 120 39%)
15-16 72 (23%)
treated volume (cm
3)
median 1.88
range 0.03-18.1
treated volume (cm
3)
median 2.81
range 0.2-23.7
Minniti et al. Radiation Oncology 2011, 6:48
http://www.ro-journal.com/content/6/1/48
Page 3 of 9histologies were lung, breast, and melanomas. The most
common location was parietal lobe followed by frontal
and temporal lobe. According to RTOG recursive parti-
tioning analysis (RPA) classes for brain metastases, 49
(24%) patients were in RPA Class I, 133 (65%) patients
in RPA Class II, and 24 (11%) patients in RPA Class III.
One hundred and fifty-six patients received chemother-
apy before treatment or during the subsequent follow-
up. Data were reported to September 2010. At this time
91 patients were alive.
The median GTV was 1.88 cm
3 (range 0.03-18.1 cm
3),
and the median PTV was 2.81 cm
3(range 0.2-23.7 cm
3).
Mean prescribed dose was 18 Gy (range 15-20 Gy) at a
median isodose of 87% (range 84-91). The average
homogeneity index was 1.1 (range 1-1.3), and the med-
ian conformality index was 1.6 (range 1.1-2.7).
Overall survival and brain control
At a median clinical follow-up of 9.4 months (range 2-
42 months) median survival and brain control were 14.1
months and 10 months, respectively (Figure 1). The 1-
year and 2-year survival rates were 58% and 24%, and
respective brain control rates were 43% and 22%.
Seventy-nine percent of patients succumbed to their
extracranial disease and 21% of patients died of progres-
sive intracranial disease. Intracranial tumor progression
at either distant or local sites in the brain was observed
in 74 patients. Sixty-three patients had new brain metas-
tases at distant sites. The 6-month and 12-month
actuarial rates of developing new brain metastases were
26% and 50%, respectively. Sixteen patients recurred
locally after SRS. The 1-year and 2-year local control
rates were 92% and 84%, respectively. Salvage WBRT
was applied in 47 patients and salvage SRS in 21
patients. Ninety-two (30%) metastases had a complete
response, 106 (34%) had a partial response, and 112
(36%) remained stable. A clinical neurological
improvement of pre-RT existing symptoms was
recorded in 26 out of 77 patients (34%) during the fol-
low-up.
Analysis of prognostic factors showed that extracranial
disease, KPS, number of metastases, and RPA class were
significant predictive factors for survival (Table 2). His-
topathological type, age, and sex were not shown to be
a significant factor. On multivariate analysis stable extra-
cranial disease and KPS > 70 were associated with the
most significant survival benefit. RPA class was not
included in the multivariate analysis because it is not
independent of age, KPS and extracranial disease status.
Univariate analysis showed that control of extracranial
disease (P = 0.01), KPS > 70 (P = 0.03), and number of
metastases (1 vs >1, P = 0.01) were significant predictive
factors for brain control; however, only extracranial dis-
ease (P = 0.001) and number of metastases (P = 0.03)
were independent predictors on multivariate analysis.
No significant prognostic factors were associated with
local control.
Analysis of complications
Brain radionecrosis, as suggested by MR imaging or
confirmed by histology (n = 12), was the most important
complication occurring in 75 (24%) out of 310 treated
lesions. Radionecrosis was symptomatic in 31 (10%) and
asymptomatic in 44 (14%) of the treated lesions. Median
time to symptomatic and asymptomatic necrosis were
11 months (range 2-32 months) and 10 months (range
2-30 months), respectively. Neurological deficits asso-
ciated with radionecrosis including seizure, motor defi-
cits, cognitive deficits, and speech deficits are shown in
Table 3. Seizures occurred in 3 patients without evi-
dence of any radiological change suggestive of radione-
crosis. Overall, neurological complications were
recorded in 28 (13.5%) patients, being severe (RTOG
Grade 3 and 4) in 12 (5.8%) patients and requiring sur-
gery or medical treatment. Steroid dependency occurred
in 34 patients, with 16 patients who received high-dose
dexamethasone for more than 4 months. Other compli-
cations were represented by headache, hydrocephalus,
hemorrhage in 5%, 2%, and 2%, respectively. Overall,
neurological and nonneurological complications
occurred in 23% of patients.
Univariate analysis showed that KPS, tumor volume,
parietal location, and V10 through V16 Gy were signifi-
cant variables for either symptomatic or asymptomatic
brain necrosis (Table 4). The results of the Cox regres-
sion analysis showed that V10 Gy and V12 Gy were the
most predictive independent risk factors for radionecro-
sis (p = 0.0001). The correlation was more significant
for symptomatic than asymptomatic brain necrosis. In a
subsequent analysis we have evaluated the incidence of
events according to the V10 and V12 Gy quarpercentiles
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Figure 1 Kaplan-Meier analysis of overall survival, brain
control, and local control
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Page 4 of 9distribution. At a median follow-up of 9.4 months V10
Gy radionecrosis rates were 2.6% for volumes <4.5 cm
3
(1
st quartile, Q1), 11% for volumes of 4.5-7.7 cm
3 (2
nd
quartile, Q2), 24% for volumes of 7.8-12.6 cm
3 (3
rd
quartile, Q3), and 47% for volumes >12.6 cm
3 (4
th quar-
tile, Q4). The V12 Gy radionecrosis rates were the same
for volumes < 3.3 cm
3 (Q1), 3.3-5.9 cm
3 (Q2), 6.0-10.9
cm
3 (Q3), and >10.9 cm
3 (Q4). For V10 Gy > 19.1 cm
3
and V12 Gy > 15.4 cm
3 corresponding to the 90
th per-
centile the risk of radionecrosis was 62%. The actuarial
risk at 1 year for the development of brain radionecrosis
was 0% in Q1, 16% in Q2, 24% in Q3, and 51% for V12
Gy (Figure 2).
Salvage treatment for intracranial/local progression
Forty-seven patients received WBRT and 21 patients
received further SRS for intracranial progression. Patient
receiving WBRT were subsequently excluded from the
analysis. Among these patients, the median time to pro-
gression was 6 months (range 2-32 months). Median
survival after WBRT was 6.7 months. Local progression
was treated with resection in 8 patients and WBRT or
SRS in 6 patients. Histopathological evaluation of surgi-
cally treated lesions showed tumor progression in all
patients.
Discussion
In the present study we have evaluated the clinical out-
come and the risk of treatment-related complications in
206 patients treated with SRS as initial treatment for 1-3
brain metastases. Median overall survival and brain
Table 2 Univariate and multivariate survival analysis
Variable No. of patients Survival time Median months univariate analysis
P value
Multivariate analysis
Hazard ratio (95% CI) P value
Sex 0.1
Male 109 13.5
Female 97 14.7
Age (years) 0.1
< 65 122 14.6
≥ 65 84 13.3
KPS <0.0001 2.2 (1.4-3.4) 0.007
≤ 70 95 10.1
>70 111 16.1
No of brain metastases 0.03 1.5 (1-2.2) 0.1
1 126 14.7
2-3 80 13.1
Primary tumor 0.2
Lung cancer 106 13.9
Breast cancer 38 18.2
Melanoma 34 12.7
Others 28 13.1
Extracranial disease <0.0001 3.1 (1.8-5.0) <0.001
stable 90 17.2
active 116 9.8
RPA Class <0.0001
Class I 49 19.2
Class II 133 11.3
Class III 24 7.3
Table 3 Incidence of complications associated with SRS
among 310 metastases
Type of complication* No/Total (%)
seizure 16 (5.2)
motor deficits 9 (2.9)
sensor deficits 4 (1.3)
cognitive deficits 3 (1.0)
speech deficits 4 (1.3)
visual deficits 2 (0.6)
ataxia 5 (1.6)
headache 15 (5)
nausea 3 (1.0)
hemorrhage 5 (1.6)
Cushing syndrome 7 (2.3)
* Twelve patients had multiple neurological deficits
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Page 5 of 9control were 14.1 months and 10 months, respectively.
The 1-year and 2-year survival rates were 58% and 24%,
and respective brain control rates were 43% and 22%.
Sixteen patients recurred locally after SRS with 1-year
and 2-year local control of 92% and 84%, respectively.
The reported results are in accordance with previous
series of SRS for brain metastases that report a median
survival ranging from 7 to14 months [1-8].
Surgery, WBRT, and SRS alone or in combination
have been employed as treatment option for patients
with either single or multiple brain metastases, although
their optimal treatment is still an issue that remains
open for debate. Survival advantages with the use of
SRS alone or in conjunction with WBRT have been
reported by several randomized trials [2,5,7,8]. In a ser-
ies of 132 patients with 1-4 brain metastases randomly
assigned to receive WBRT plus SRS or SRS alone
Aoyama et al [7] reported no significant difference in
survival (8 months versus 7.5 months) and 1-year local
control (72.5% versus 88.7%). Although SRS alone was
associated with increased intracranial progression as
compared with WBRT plus SRS, no differences in the
frequency of neurologic deaths and preservation of neu-
rologic function were observed. Similarly, the recent
EORTC 22952-26001 study on the adjuvant WBRT ver-
sus observation after SRS or surgical resection of 1-3
cerebral metastases showed that adjuvant WBRT was
able to reduce the frequency of intracranial progression
but failed to improve the median survival [8]. Few stu-
dies have compared SRS with or without WBRT versus
resection plus WBRT, with the majority of them report-
ing no differences in survival and neurological deaths
between groups [31-35]. In a retrospective analysis of
206 patients with one or two metastases, Rades et al
[35] reported a similar outcome in patients treated with
WBRT plus SRS or surgery plus WBRT and boost. The
1-year survival and brain control rates were 65% and
70% after WBRT plus SRS, and 63% and 78% after sur-
gery plus WBRT and boost, respectively. Based on the
present results and published data, SRS alone as initial
treatment strategy in patients with either single or mul-
tiple metastases is a feasible therapeutic option asso-
ciated with high local control and survival benefits,
although the superiority of SRS versus other treatment
options in terms of improved survival remains to be
demonstrated. Certainly, the high 1-year brain tumor
recurrence rates of about 50% after SRS alone clearly
indicates that a frequent monitoring of intracranial dis-
ease is mandatory for such patients.
On multivariate analysis, KPS >70 and stable extracra-
nial disease were significantly associated with longer sur-
vival. Number of metastases did not emerge as
significant variable associated with the outcome similarly
Table 4 Univariate and multivariate analysis of radiation-
induced brain necrosis
Variables Univariate analysis Multivariate analysis
Age 0.2
Gender 0.3
KPS 0.04 0.1
Tumor volume <0.0001 0.02
Dose 0.09
Conformality index 0.04 0.2
Homogeneity index 0.1
lung histology 0.1
Melanoma histology 0.3
Breast histology 0,2
frontal location 0.2
parietal location 0.03 0.1
temporal location 0.3
cerebellar location 0.2
occipital location 0.3
brainstem location 0.9
V10 Gy <0.0001 0.001*
V12 Gy <0.0001 0.001**
V14 Gy <0.0001 0.005°
V16 Gy 0.0001 0.009°°
V18 Gy 0.001 0.05^
*0.003 for symptomatic and 0.04 for asymptomatic brain necrosis
**0.003 for symptomatic and 0.04 for asymptomatic brain necrosis
°0.01 for symptomatic and 0.1 for asymptomatic brain necrosis
°°0.02 for symptomatic and 0.3 for asymptomatic brain necrosis
^0.03 for symptomatic and 0.5 for asymptomatic brain necrosis
     Time (months) 
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Figure 2 Risk of brain radionecrosis after stereotactic
radiosurgery for brain metastases in relation to brain volumes
receiving 12 Gy (V12 Gy) stratified for quartiles (Q1-Q4). The
risk increased significantly through Q1-Q4, corresponding to V12 Gy
< 3.3 cm
3, 3.3-5.9 cm
3, 6.0-10.9 cm
3, and >10.9 cm
3, respectively.
The actuarial risk at 1 year was 0% for Q1, 16% for Q2, 24% for Q3,
and 51% for Q4
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lished series [12,36]. The high local control after SRS
and the improved control of extracranial disease
reported with the combination of cytotoxic and targeted
agents [37-41] may, at least in part, explain these results.
Similarly, older age did not have a negative impact on
survival, suggesting that SRS is a feasible and safe
approach also in this subgroup of patients [42,43].
Brain necrosis represents the most important late toxi-
city reported after SRS, leading to neurological compli-
cations in 2-32% of patients [1-10,18-20]. At doses of
16-22 Gy usually employed for the radiosurgical treat-
ment of brain metastases, radionecrosis has been
reported in up to 50% of treated lesions, with radiation
dose, tumor volume and location of the lesion being the
most important predictive variables [22-26]. In our
study, radionecrosis occurred in 24% of treated lesions
with SRS, leading to severe neurological complications
(RTOG Grade ≥ 3) in 5.8% of patients. Other adverse
events included headache, iatrogenic Cushing syndrome,
and more rarely conditions as haemorrhage and hydro-
cephalus. The present results confirm that SRS is asso-
ciated with a relatively high rate of treatment-related
complications as reported by some authors, although
with an acceptable incidence of severe neurological defi-
cits [18-21].
Analysis of risk factors for brain necrosis showed
t h a tV 1 0G ya n dV 1 2G yw e r et h em o s ti m p o r t a n t
independent predictors of both symptomatic and
asymptomatic radionecrosis. At a median follow-up of
9.4 months the actuarial risk at 1 year for the develop-
ment brain radionecrosis increased significantly
through Q1-Q4, being 0% in Q1, 16% in Q2, 24% in
Q3, and 51% in Q4. Our data are consistent with pre-
vious studies that have shown a significant correlation
b e t w e e nv o l u m er e c e i v i n gad o s eo f1 0o r1 2G ya n d
the development of radionecrosis in patients treated
with SRS for brain metastases and other intracranial
tumors [21,22,25,26]. Blonigen et al [26] in a series of
63 patients with a total of 173 brain metastases treated
with SRS have reported a significant radionecrosis risk
up to 68.8% for V10 Gy >14.5 cm
3 and V12 Gy >10.8
cm
3, respectively. In contrast, no cases of radionecrosis
were found for V10 Gy < 0.68 cm
3 and V12 Gy < 0.5
cm
3. In a retrospective analysis of 198 intracranial
tumors treated with Gamma Knife SRS, Korytko et al
[25] confirmed the correlation between the V12 Gy
and the risk of symptomatic radionecrosis. The risk
was 55.3% for V12 Gy > 10 cm
3 versus 22.5% for V12
Gy < 10 cm
3, being significant in multivariate analysis.
In contrast, the risk for asymptomatic radionecrosis
did not increase with V12 Gy, remaining at 19.1% for
tumors <10 cm
3 and 18.5% for tumors > 10 cm
3,
respectively. Few authors have evaluated the predictive
value of volume receiving 10 or 12 Gy on the develop-
ment of radionecrosis after SRS for arteriovenous mal-
formation (AVM) [21,22]. At a median follow-up of 28
months Voges et al [22] reported an actuarial risk of
radionecrosis of 38.4% at 2 years in 62 patients with
intraparenchymal lesions, with an incidence of events
of 0% for volumes covered by the 10 Gy isodose-line
≤10 cm
3 and 23.7% for volumes >10 cm
3.F l i c k i n g e re t
al [21] in a series of 307 patients with AVM who
received GK SRS at the University of Pittsburgh
between 1987 and 1993 observed an incidence of
symptomatic radionecrosis of 30.5% at 7 years. On
multivariate analysis, V12 Gy and AVM location were
the only independent variable that correlated signifi-
cantly with brain necrosis.
Although the reported risk of radionecrosis after SRS
is variable in the published series depending on different
radiosurgical techniques, type of lesion treated, length of
follow-up and patient’s selection, nevertheless volume
receiving 12 Gy may be adopted as the standard method
of reporting the dose to the normal brain to estimate
the risk of toxicity after SRS. In our department brain
metastases with a V12 Gy >8.5 cm
3, which is the mid-
point of 3
rd quartile corresponding to the risk of devel-
oping radionecrosis >10% at 1 year, are considered for
hypofractionated stereotactic radiotherapy using a dose
of 24-27 Gy in 3 fractions rather than single SRS to
reduce the risk of treatment-related complications.
In conclusion, SRS represents a feasible option for
patients with brain metastasesa s s o c i a t e dw i t hs u r v i v a l
benefit, however a significant subset of patients may
develop neurological complications. Radionecrosis repre-
sents the most important late toxicity after SRS with the
brain volumes irradiated at 10 and 12 Gy being the
most important independent predictors of brain necro-
sis. Large lesions at high risk of radiation-induced com-
plications especially when located in/near eloquent areas
should be considered for hypofractionated stereotactic
radiotherapy.
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